Here we report the case of a 57-year-old man who underwent resection of a dural-based hemangiopericytoma (HPC) in the left frontoparietal region. The patient was treated with radiation therapy and remained symptomfree for 10 years. At 67 years of age, he presented with a mass in the left frontal region near the same area as the first tumor, in addition to a separate smaller mass in the right middle cranial fossa. Resection of the larger left frontal mass revealed an HPC. Follow-up imaging 9 months later showed a significant increase in size of the right middle cranial fossa mass. This third mass was resected, and histological examination also demonstrated an HPC.
H emangiopericytoma (HPC) was fi rst described in 1942 by Stout and Murray as a highly vascularized tumor arising from the pericytes of Zimmerman, the modifi ed smooth muscle cells that surround capillaries and postcapillary venules ( 1 ) . In 1954, Begg and Garret fi rst reported a case of an HPC occurring in the nervous system ( 2 ) . Th ese are rare neoplasms representing 2.5% of all meningeal tumors and 0.4% of all intracranial tumors ( 3 ) . Th e 2007 World Health Organization (WHO) criteria developed a two-tiered system for grading intracranial HPCs, including WHO grade II and grade III (anaplastic) ( Table 1 ) ( 4 ). In the largest published review of meningeal HPC, including follow-up data on 277 patients, local recurrence was seen in 57% of patients and systemic metastases was seen in 27% ( 5 ). Isolated intracranial metastasis remains an unusual event. Th e overall literature on intracranial HPC remains limited, especially concerning long-term follow-up of patients ( 6 , 7 ) .
CASE REPORT
A 57-year-old man without any signifi cant family history or past medical history underwent resection of an extra-axial mass in the left frontoparietal region. Th e pathologic diagnosis of this fi rst tumor was HPC, WHO grade III. Th e patient was treated with radiation therapy and remained symptom-free for approximately 10 years.
When the patient was 67 years of age, radiologic imaging showed an enhancing partially cystic extra-axial mass in the left frontal region ( Figures 1 a and 1 b) . Another smaller mass was also visualized in the right middle cranial fossa ( Figure 1 c) . He underwent resection of the larger left frontal mass, and histological examination revealed an HPC, WHO grade III. Follow-up imaging 9 months later revealed a signifi cant increase in size of the right middle cranial fossa mass ( Figure 1 d) , which did not appear to have obvious connection to the previous two masses. Th e decision was made to proceed with resection of this third mass due to its rapid growth rate. Histological examination again revealed an HPC, WHO grade III. Subsequent imaging ruled out systemic metastases. At 1 year postresection, the patient does not have any additional symptoms and continues to be an active rancher.
Th e original left frontoparietal mass (the fi rst of the three tumors) was highly cellular with a very rich vascular network ( Figure 2 a) . Th e vascular channels displayed a staghorn-like appearance. Multifocal necrosis and hemorrhage were identifi ed. Th e mitotic activity was up to 5 mitotic fi gures per 10 highpower fi elds. Immunohistochemical studies showed prominent Th e patient's mass in the left frontal region, which was removed 10 years later, showed histopathology characteristics similar to those of the fi rst tumor ( Figure 2 b) . Reticulin staining highlighted the rich microvascular network ( Figure 2 c) . As with the original tumor, CD34 reactivity was diff usely positive and epithelial membrane antigen was negative. Th e morphology and staining patterns were again diagnostic of an HPC, WHO grade III.
The right middle fossa mass was resected 9 months after the second left frontal mass and was microscopically similar to the previous tumors ( Figures  2 d and 2 e) . Mitotic activity was focally brisk with up to 5 mitotic fi gures per 10 high-power fi elds. Th ere was multifocal coagulative necrosis ( Figure 2 f ) . Immunohistochemistry showed tumor cells to be diff usely and strongly immunoreactive for CD34 ( Figure 2 g ) and CD99 ( Figure 2 h ), whereas keratin, epithelial membrane antigen, and smooth muscle actin were negative. Th ese fi ndings were again diagnostic of an HPC, WHO grade III.
DISCUSSION
Th e multifocal presentation of intracranial HPCs can have three explanations: 1) recurrence of a previously resected HPC; 2) metastasis of an HPC to other intracranial, dural-based locations; or 3) development of independent HPCs at diff erent sites. In the present case, it is most likely that the second tumor was a recurrence of the primary tumor resected 10 years earlier since the second HPC arose at a site very close to the fi rst HPC (left frontoparietal region). Th e third dural-based HPC, however, developed in an entirely separate area of the brain (in the right middle fossa), relatively distant from the site of the fi rst two HPCs. Th ere is no specifi c vascular connection favoring this particular spread; however, there is a possible, although distant, cerebrospinal fl uid connection. It is less likely that the third HPC developed independently of the fi rst two HPCs. In most cases of intracranial HPC with reported recurrence and/or metastases, recurrence at the primary tumor site is usually followed by systemic rather than intracranial metastases.
Th e interesting feature of this particular case is the lack of systemic metastases in the setting of an unusual intracranial metastasis from one dural-based location to another without an obvious connection. Since recurrence with a greater degree of malignancy can develop following an extended disease-free interval, this case highlights the importance of careful long-term follow-up for patients with HPC. 
